Get the Stockscreener App
9.44
0.74%
-0.07
Zevra Therapeutics Inc stock is traded at $9.44, with a volume of 1.21M.
It is down -0.74% in the last 24 hours and down -18.48% over the past month.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
See More
Previous Close:
$9.51
Open:
$9.55
24h Volume:
1.21M
Relative Volume:
1.11
Market Cap:
$529.92M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-7.3178
EPS:
-1.29
Net Cash Flow:
$-33.83M
1W Performance:
+0.11%
1M Performance:
-18.48%
6M Performance:
+22.92%
1Y Performance:
+30.03%
1-Day Range:
$9.2734
$9.8291
1-Week Range:
$8.91
$10.15
52-Week Range:
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(321) 939-3416
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Compare ZVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
9.44 | 516.44M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-08-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
ZEVRA THERAPEUTICS Director John B Bode Acquires 5,000 Shares - TradingView
Zevra Therapeutics Faces $58.7 Million Impairment Charge, Raising Concerns Over Financial Stability - MSN
Is Zevra Therapeutics Inc. stock a falling knife or bargain buyWeekly Trading Summary & Capital Efficiency Focused Ideas - newsyoung.net
Institutional Investors in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Lost 22% Last Week but Have Reaped the Benefits of Longer-term Growth - 富途牛牛
Zevra Therapeutics’ Earnings Call: Optimism Amid Challenges - MSN
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised) - sharewise.com
Zevra signals continued MIPLYFFA momentum with 26% revenue growth and $150M PRV sale strengthening balance sheet - MSN
Zevra Therapeutics Q2 Earnings Top Revenue Estimates, Shares Up 40% YTD - AInvest
Can Zevra Therapeutics Inc. Outperform Peers After Recent PullbackWeekly Stock Recap & Risk Controlled Daily Trade Plans - sundaytimes.kr
How do insiders feel about Zevra Therapeutics Inc.Weekly Trading Summary & Accurate Buy Signal Notifications - thegnnews.com
Zevra Therapeutics’ SWOT analysis: stock soars on MIPLYFFA success, pipeline potential - Investing.com
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates - MSN
Zevra Therapeutics at Canaccord Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.' - inkl
JMP Securities maintains Market Outperform on Zevra, lowers PT to $18. - AInvest
Price Channel Expanding on Zevra Therapeutics Inc.’s ChartShort Setup & Risk Controlled Swing Alerts - sundaytimes.kr
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2025 Earnings Call Transcript - Insider Monkey
Zevra Therapeutics: Strong Buy Rating Amid U.S. Growth and EU Market Potential - TipRanks
Zevra Therapeutics price target lowered to $18 from $19 at Citizens JMP - TipRanks
Zevra Therapeutics shares fall 9.01% premarket despite Q2 profit and revenue growth. - AInvest
Zevra Therapeutics reports Q2 EPS $1.21, consensus $1.38 - MSN
Zevra Therapeutics stock price target lowered to $18 at Citizens JMP - Investing.com Australia
Zevra Therapeutics stock price target lowered to $18 at Citizens JMP By Investing.com - Investing.com South Africa
Zevra Therapeutics shares fall 10.54% premarket despite Q2 revenue beating estimates. - AInvest
Zevra Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Zevra Therapeutics Inc (ZVRA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Zevra Revenue Jumps 486 Percent in Q2 - AOL.com
Zevra Therapeutics Inc (ZVRA) Q2 2025 Earnings Call Highlights: - GuruFocus
Zevra Therapeutics Inc (ZVRA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Zevra Reports Second Quarter 2025 Financial Results and Corporate Update - GlobeNewswire
Zevra Therapeutics Reports Strong Q2 2025 Results - TipRanks
Zevra Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Zevra Therapeutics' Q2 2025 Earnings Call: Unraveling Contradictions in Patient Enrollment Strategies and Reimbursement Timelines - AInvest
Zevra Therapeutics (ZVRA) Reports Strong Q2 2025 Financials - GuruFocus
Transcript : Zevra Therapeutics, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Zevra Therapeutics Outpaces Earnings Estimates And Investor Optimism Builds - Finimize
Earnings call transcript: Zevra Therapeutics Q2 2025 misses EPS, revenue shines - Investing.com
ZEVRA THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Zevra Q2 2025 net revenue at $25.9mln, arimoclomol approval sought in EU - AInvest
Zevra Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Zevra Therapeutics Q2 Swing to Profits, Revenue Rises - MarketScreener
Zevra Therapeutics earnings missed by $2.25, revenue topped estimates - Investing.com Canada
Zevra Therapeutics falls as significant earnings miss overshadows revenue beat - Investing.com Nigeria
Zevra Therapeutics' Q2 Earnings Outperformance and Strategic Momentum in Rare Disease Therapies: A Deep Dive into Long-Term Investment Viability - AInvest
Zevra Therapeutics Q2 revenue beats estimates - MarketScreener
Zevra Therapeutics Q2 Non-GAAP EPS Misses by $1.44, Revenue Surpasses Expectations - AInvest
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zevra Therapeutics Inc Stock (ZVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thompson Rahsaan | Chief Legal & Compliance |
Jun 26 '25 |
Sale |
9.21 |
24,000 |
221,004 |
42,666 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):